| Somatotropin deficiency
Ngenla vs Skytrofa
Side-by-side clinical, coverage, and cost comparison for somatotropin deficiency.Deep comparison between: Ngenla vs Skytrofa with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsSkytrofa has a higher rate of injection site reactions vs Ngenla based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Skytrofa but not Ngenla, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Ngenla
Skytrofa
At A Glance
SC injection
Once weekly
Growth hormone analog
SC injection
Once weekly
Pegylated growth hormone prodrug
Indications
- Somatotropin deficiency
- Somatotropin deficiency
Dosing
Somatotropin deficiency 0.66 mg/kg based on actual body weight administered SC once weekly; individualize dosage based on growth response. When switching from daily growth hormone, initiate NGENLA on the day following the last daily injection.
Somatotropin deficiency (pediatric) 0.24 mg/kg body weight SC once weekly; individualize and titrate based on response.
Somatotropin deficiency (adult) Starting dose 0.7-2.1 mg SC once weekly based on age and concomitant oral estrogen use; titrate monthly based on clinical response and/or IGF-1 concentration; maximum 6.3 mg once weekly.
Contraindications
- Acute critical illness after open heart surgery, abdominal surgery, multiple accidental trauma, or acute respiratory failure
- Hypersensitivity to somatrogon-ghla or any excipient in NGENLA
- Closed epiphyses
- Active malignancy
- Active proliferative or severe non-proliferative diabetic retinopathy
- Prader-Willi syndrome with severe obesity, history of upper airway obstruction or sleep apnea, or severe respiratory impairment
- Acute critical illness after open heart surgery, abdominal surgery, multiple accidental trauma, or acute respiratory failure
- Hypersensitivity to somatropin or any excipient in SKYTROFA
- Closed epiphyses in pediatric patients
- Active malignancy
- Active proliferative or severe non-proliferative diabetic retinopathy
- Prader-Willi syndrome in pediatric patients who are severely obese, have a history of upper airway obstruction or sleep apnea, or have severe respiratory impairment
Adverse Reactions
Most common (>=5%) Injection site reactions, nasopharyngitis, headache, pyrexia, anemia, cough, vomiting, hypothyroidism, abdominal pain, rash, oropharyngeal pain
Serious Increased mortality in acute critical illness, severe hypersensitivity, increased risk of neoplasm, glucose intolerance and diabetes mellitus, intracranial hypertension, fluid retention, hypoadrenalism, hypothyroidism, slipped capital femoral epiphysis, progression of preexisting scoliosis, pancreatitis, lipoatrophy, sudden death in pediatric patients with Prader-Willi syndrome
Postmarketing Osteonecrosis in pediatric patients
Most common (>= 5%) Viral infection, pyrexia, cough, nausea and vomiting, hemorrhage, diarrhea, abdominal pain, arthralgia and arthritis (pediatric); edema, central hypothyroidism (adult)
Serious Increased mortality in acute critical illness, severe hypersensitivity, neoplasms, glucose intolerance and diabetes mellitus, intracranial hypertension, fluid retention, hypoadrenalism, hypothyroidism, slipped capital femoral epiphysis, progression of preexisting scoliosis, pancreatitis, lipoatrophy, sudden death in Prader-Willi syndrome pediatric patients
Postmarketing Severe systemic hypersensitivity reactions including anaphylactic reactions and angioedema, osteonecrosis in pediatric patients
Pharmacology
Somatrogon-ghla is a human growth hormone analog that binds to the GH receptor and activates the STAT5b signaling pathway, increasing serum IGF-1 concentrations and stimulating linear growth and metabolic changes in pediatric patients with growth hormone deficiency.
Lonapegsomatropin-tcgd is a pegylated prodrug of somatropin that releases active growth hormone via autocleavage of the TransCon linker; somatropin binds the growth hormone (GH) receptor, driving IGF-1-mediated and direct effects including chondrocyte differentiation and proliferation, hepatic glucose output, protein synthesis, lipolysis, and skeletal growth at the epiphyses of long bones.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Ngenla
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (10/12) · Qty limit (9/12)
Skytrofa
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (5/12) · Qty limit (9/12)
UnitedHealthcare
Ngenla
- Covered on 4 commercial plans
- PA (5/8) · Step Therapy (0/8) · Qty limit (4/8)
Skytrofa
- Covered on 4 commercial plans
- PA (4/8) · Step Therapy (0/8) · Qty limit (4/8)
Humana
Ngenla
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (3/3) · Qty limit (0/3)
Skytrofa
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (3/3) · Qty limit (2/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
$0/momo
Ngenla Copay ProgramCommercial or private insurance
Medicare, Medicaid, VA, TRICARE
$5/momo
A·S·A·P Co-pay Program: SkytrofaCommercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
NgenlaView full Ngenla profile
SkytrofaView full Skytrofa profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.